Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2003;5(6):296-9.
doi: 10.1186/bcr648. Epub 2003 Oct 1.

Should all adjuvant breast cancer patients receive a bisphosphonate?

David A Cameron  1
Affiliations
Editorial

Should all adjuvant breast cancer patients receive a bisphosphonate?

David A Cameron. Breast Cancer Res. 2003.

Abstract

This commentary discusses the report by Trevor Powles and colleagues on their double-blind, placebo-controlled randomised trial of 2 years' adjuvant oral clodronate. Although the reported survival benefit in the clodronate-treated group confirms the results of one prior study as well as the generally held view that bisphosphonates could be advantageous, the reviewer does not feel that the data support the universal use of this additional adjuvant therapy.

PubMed Disclaimer

References

    1. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer [comment] J Clin Oncol. 2002;20:3219–3224. doi: 10.1200/JCO.2002.11.080. - DOI - PubMed
    1. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis [review] [75 refs] Am J Clin Oncol. 2002;25:S3–S9. doi: 10.1097/00000421-200212001-00002. - DOI - PubMed
    1. Van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone. 2002;30:64–70. doi: 10.1016/S8756-3282(01)00655-X. - DOI - PubMed
    1. Jagdev SP, Coleman RE, Shipman CM, Rostami H, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001;84:1126–1134. doi: 10.1054/bjoc.2001.1727. - DOI - PMC - PubMed
    1. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999;83:263–269. doi: 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T. - DOI - PubMed

Publication types